Erlotinib Hydrochloride

Kar AK, et al. Intelligent Pharmacy, 2024.

This study explores the development and optimization of microsponges incorporating Erlotinib Hydrochloride (ETB) for controlled drug delivery. The microsponges were fabricated using a quasi-emulsion solvent diffusion technique, a process that leverages water-soluble and enzyme-sensitive components, such as ethyl cellulose (EC) and pectin, to enhance the drug's release profile. The fabrication involved a two-stage process: the preparation of the internal phase, where varying molar ratios of pectin and EC (1:1, 1:2, 1:4) were dissolved in a solvent mixture of isopropanol and dichloromethane (1:1), followed by the incorporation of 100 mg of ETB and 0.5% w/v magnesium stearate.
The internal phase was then added to liquid paraffin, with stirring speeds of 300, 500, or 1000 rpm, at 10°C for 7 hours. After the formation of the oil-in-oil emulsion, the system was heated to 35°C and stirred for 90 minutes to enable the solvent to diffuse out. The microsponges were purified through filtration with n-hexane to eliminate residual contaminants and stored in a hot air oven at 50°C for 8 hours.
The resulting microsponges showed significant potential for controlled and sustained release of ETB, which is critical for improving therapeutic efficacy and minimizing side effects in cancer treatment. This method represents an innovative approach for enhancing the bioavailability and targeting of Erlotinib Hydrochloride in pharmaceutical formulations.

Wang X, et al. Journal of Drug Delivery Science and Technology, 2024, 91, 105200.

This study investigates the formation of a co-amorphous system of ERL with gallic acid (GA) to enhance its solubility and therapeutic potential.
The co-amorphous system was synthesized using a solvent evaporation method. A mixture of ERL (86 mg) and GA (68.1 mg) was prepared in a 1:2 molar ratio and dissolved in 40 mL of methanol. The solvent was then evaporated at 40°C under reduced pressure for 30 minutes, followed by further drying in a vacuum oven at 30°C for 24 hours to remove residual solvent. The resulting solid was characterized as a co-amorphous mixture (ERL-GA CM), which was compared to a physical mixture (ERL-GA PM) prepared by simply blending the two components in the same molar ratio.
The co-amorphous ERL-GA CM demonstrated improved solubility compared to the physical mixture, suggesting that the amorphous state of the drug-co-former complex enhances the dissolution rate, which is expected to lead to better bioavailability. This study provides a promising approach for improving the pharmacokinetic profile of ERL, potentially improving its clinical outcomes in cancer treatment.

Vrignaud S, et al. International Journal of Pharmaceutics, 2012, 436(1-2), 194-200.

In this study, Erlotinib hydrochloride (ERL) was incorporated into lipid nanocarriers through reverse micelle encapsulation. The aim of the study was to optimize the formulation of ERL-loaded nanoparticles.
Incorporation of ERL into Reverse Micelles: This step involves incorporating the drug into reverse micelles composed of surfactant and Labrafac oil, which is the initial stage in the production of reverse micelle-based nanocapsule formulations. A weighed amount of ERL powder (10-50 mg) was added to the reverse micelle, which had a final volume of 2 mL. The mixture was incubated for 30 minutes and heated to 70°C to allow for the encapsulation of ERL into the reverse micelles. The ERL-loaded reverse micelles were then separated by centrifugation (5 minutes at 13,400 rpm). Any undissolved ERL was dissolved in 2 mL of DMSO, and the ERL content was quantified by UV-visible spectroscopy at 333 nm. The amount of ERL in the reverse micelles was determined by calculating the difference between the initial amount of ERL and the amount of undissolved ERL.
Nanocarrier Formulation: In brief, a mixture consisting of 39.3% Solutol, 1.8% sodium chloride, 17.2% Labrafac®, and 41.7% water was prepared and heated to 90°C under magnetic stirring at 500 rpm. After slow cooling to 85°C, 3 mL of the reverse micelle formulation was added to the mixture. The system was allowed to cool to the phase inversion temperature (PIT) of approximately 75°C, at which point the mixture was rapidly diluted with cold water (with the dilution volume being six times the volume of water in the mixture prior to dilution) to generate the nanocarriers.